Form 4 Aquestive Therapeutics Inc For: 17 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc stock price live, this page displays NASDAQ AQST stock exchange data. View the AQST premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aquestive Therapeutics Inc real time stock price chart below.
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 3.695.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock symbol for Aquestive Therapeutics Inc is "AQST."
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
What Is the Aquestive Therapeutics Inc Stock Price Today?
The Aquestive Therapeutics Inc stock price today is 3.695.
What Is the Stock Symbol for Aquestive Therapeutics Inc?
The stock symbol for Aquestive Therapeutics Inc is "AQST."
What Stock Exchange Does Aquestive Therapeutics Inc Trade On?
Aquestive Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Aquestive Therapeutics Inc a Good Stock to Buy?
Determining whether Aquestive Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AQST quote. (ISIN: US03843E1047)
Fair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.605
3.780
52 wk Range
2.930
7.550
Earnings results expected in 10 days
1/2
Fair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.6053.780
52 wk Range
2.9307.550
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AQST Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Aquestive Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.889
Upside
+140.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Form 144 Aquestive Therapeutics For: 23 June- Investing.com
Form 4 Aquestive Therapeutics Inc For: 16 June- Investing.com
Form S-3 Aquestive Therapeutics Inc For: 26 June- Investing.com
- Form 4 Aquestive Therapeutics Inc For: 17 July
- Investing.com
- Form S-3 Aquestive Therapeutics Inc For: 26 June
- Investing.com
Form 4 Aquestive Therapeutics Inc For: 24 June- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.889
(+140.57% Upside)
Aquestive Therapeutics Inc SWOT Analysis
Needle-Free Revolution | Explore Aquestive's Anaphylm, a groundbreaking needle-less epinephrine delivery system poised to transform anaphylaxis treatment and expand market reach |
Clinical Triumph | Delve into Anaphylm's robust clinical data, showcasing comparable efficacy to existing treatments and rapid absorption crucial for emergency situations |
Market Potential | Analyst projections estimate peak sales of $700 million by 2035, with price targets ranging from $4.75 to $15 per share for this innovative treatment |
Strategic Positioning | Learn how Aquestive's improved financial outlook and strategic funding support its long-term growth strategy in the competitive epinephrine market |
Aquestive Therapeutics Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of -$0.07 beat forecast of -$0.13 by 46%; revenue surged 66% YoY to $14.4M vs. $10.9M expected, driving 11% premarket stock gain.
- Net loss narrowed to $8.1M from $22.9M in Q1 2025; operating expenses cut 42%, particularly in SG&A, reflecting improved operational efficiency.
- License and royalty revenue jumped to $5.4M from $0.8M YoY; company maintains strong cash position with current ratio of 3.14 and more cash than debt.
- 2026 revenue guidance set at $46M-$50M with adjusted EBITDA loss of $30M-$35M; preparing for Anaphylm U.S. launch pending FDA approval.
- CEO Kendall emphasized strategic execution effectiveness; analysts maintain bullish outlook with $11 price target, suggesting significant upside from current levels.
Last Updated: 14/05/2026, 14:06
Read Full TranscriptEarnings
Latest Release
May 13, 2026
EPS / Forecast
-0.07 / -0.13
Revenue / Forecast
14.4M / 10.9M
Compare AQST to Peers and Sector
Metrics to compare | AQST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAQSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | 5.9x | −0.3x | |
PEG Ratio | 2.24 | −1.83 | 0.00 | |
Price/Book | −13.6x | 3.6x | 2.6x | |
Price / LTM Sales | 9.2x | 4.0x | 3.0x | |
Upside (Analyst Target) | 141.9% | 28.8% | 56.7% | |
Fair Value Upside | Unlock | 8.2% | 9.4% | Unlock |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Aquestive Therapeutics (AQST) Stock Price Today?
The Aquestive Therapeutics stock price today is 3.695 USD.
What Stock Exchange Does Aquestive Therapeutics Trade On?
Aquestive Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Aquestive Therapeutics?
The stock symbol for Aquestive Therapeutics is "AQST."
What Is the Aquestive Therapeutics (AQST) Afterhours Price Today? (Afterhours variable test: 3.680) Current Date: Aug 01, 2026
After hours price: 3.680. After hours price change (units): -0.015. Price change percentage: -0.410%
What Is the Aquestive Therapeutics Market Cap?
As of today, Aquestive Therapeutics market cap is 466.740M USD.
What Is Aquestive Therapeutics's Earnings Per Share (TTM)?
The Aquestive Therapeutics EPS (TTM) is -0.606.
When Is the Next Aquestive Therapeutics Earnings Date?
Aquestive Therapeutics will release its next earnings report on Aug 11, 2026.
From a Technical Analysis Perspective, Is AQST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Aquestive Therapeutics Stock Split?
Aquestive Therapeutics has split 0 times.
How Many Employees Does Aquestive Therapeutics Have?
Aquestive Therapeutics has 147 employees.
What is the current trading status of Aquestive Therapeutics (AQST)?
As of Aug 01, 2026, Aquestive Therapeutics (AQST) is trading at a price of 3.695 USD, with a previous close of 3.720 USD. The stock has fluctuated within a day range of 3.605 USD to 3.780 USD, while its 52-week range spans from 2.930 USD to 7.550 USD.
What Is Aquestive Therapeutics (AQST) Price Target According to Analysts?
The average 12-month price target for Aquestive Therapeutics is 8.889 USD, with a high estimate of 11 USD and a low estimate of 6 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +140.57% Upside potential.
What Is the AQST Premarket Price?
AQST's last pre-market stock price is 3.740 USD. The pre-market share volume is 2,640.000, and the stock has decreased by 0.020, or 0.540%.
What Is the AQST After Hours Price?
AQST's last after hours stock price is 3.680 USD, the stock has decreased by -0.015, or -0.410%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.